Compare Charles River Laboratories Intl. Inc (CRL) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Vanguard International High Dividend Yield ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $232.3 (market cap $11.14B), while Vanguard International High Dividend Yield ETF trades at $101. Which is the better fit depends on your goals.
| CRL | VYMI | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $233.60 | $101.60 |
52-Week Low | $145.57 | $79.76 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
VYMI trades at $100.06, down 0.51% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on international high-dividend stocks, offering diversification and a low 0.07% expense ratio. Recent news highlights its role in hedging against U.S. market concentration and stagflation risks, with strong dividend growth over the past three years.
Outlook remains positive due to attractive international valuations and dividend yield near 4%, though risks include currency fluctuations and global economic slowdowns. Analyst sentiment is favorable, emphasizing long-term growth potential versus U.S. equities, but investors should monitor geopolitical and interest rate impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
